Generic Name: Tranexamic Acid 500mg
Manufacturer/Distributor: Pacific Pharmaceuticals Ltd.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Indications
Medicine: prevention and treatment of parathyroid hemorrhage, gastrointestinal hemorrhage, hemorrhagic syndrome due to leukemia, liver cirrhosis and hemophilia, thrombocytopenic purpura, thrombolytic therapy, and accidents during a blood transfusion.
Surgery: Preventive and anti-bleeding treatment during surgeries of any type and nature, especially lung, cardiovascular, and abdominal surgery, as well as postoperative and traumatic shock.
Urology: Preventive and anti-hemorrhagic treatment of prostate, bladder, and kidney surgery. Hematuria
Obstetrics: prevention and treatment of postpartum and puerperal hemorrhage, hemorrhagic endometriosis, functional menorrhagia, idiopathic or intrauterine device-induced menorrhagia (intrauterine device), primitive hyperfibrinolysis (placenta detachment, placental abruption) and cervical erosion.
In the Department of Otolaryngology: tonsillectomy, general specialist surgery, prevention and anti-bleeding treatment during epistaxis.
Department of Stomatology: maxillofacial surgery, prevention, and anti-bleeding treatment during tooth extraction.
In oncology (as supportive therapy): Promotes the formation of fibrin capsules to isolate and inhibit the growth of ovarian tumors. The cause of ascites regression is secondary to cancer. Reduce bleeding during surgical intervention.
Pharmacology
This is a preparation of tranexamic acid (trans-4-aminomethyl cyclohexane carboxylic acid). Tranexamic acid is a substance with a strong antifibrinolytic effect, it has been shown to be 10 times more active than conventional hemostatic agents in vivo and in vitro, according to the test. The anti-bleeding effect of tranexamic acid is mainly due to the inhibition of plasminogen activation by exogenous activators (such as streptokinase) and endogenous activators (such as urokinase and tissue plasminogen activators). This fact is particularly important for the clinical application of tranexamic acid because it ensures anti-bleeding activity against fibrinolytic mechanisms under various conditions.
Tranexamic acid has very low acute toxicity and almost no chronic toxicity. Tranexamic acid is well absorbed orally, and the effect can be observed 1530 minutes after administration. It is mainly excreted through the kidneys, but more slowly than traditional hemostatic agents. These properties make the effect of tranexamic acid longer than traditional hemostatic agents. Therefore, a relatively low single dose of tranexamic acid can be administered over a longer time interval, and the plasma level of the drug will not drop to an ineffective antifibrinolytic activity level between two doses.
A therapeutic dose of tranexamic acid will not interfere with the coagulation process, and even long-term administration will not be accompanied by any tendency to thrombosis.
Dosage & Administration
Adults-
The usual dose: is 500-1000 mg 3 times daily.
For prophylaxis: The mean recommended daily doses are 0.5-1 gm orally, 500 mg by the parenteral (intravenous or intramuscular) route.
For therapy of hemorrhagic manifestations: the oral dose increases to 1-3 gm given in divided doses: in cases of particular seriousness and urgency, begin by injecting an ampoule (500 mg) slowly by intravenous route and administer the necessary subsequent oral doses.
Children-
For prophylaxis: For every kg of body weight from 5-10 mg is orally administered daily in divided doses.
For therapeutic purposes: The oral doses are doubled (from 10 to 20 mg/kg), while the intravenous and intramuscular treatment is begun with 10 mg/kg (=0.5 ml every 5 kg) by the slow intravenous route, continuing the oral administration up to the required dose. Where it is more convenient (e.g. in small babies) the ampoules, diluted in a little sweetened water, may be orally administered instead of the Capsules.
Elderly patients: No reduction in dosage is necessary unless there is evidence of renal failure.
Interaction
Tranexamic acid is a synthetic amino acid and is incompatible with solutions containing penicillin (such as benzylpenicillin). Thrombolytic drugs such as streptokinase and urokinase can antagonize the antifibrinolytic effect of tranexamic acid. Taking estrogen-containing drugs (such as oral contraceptives) at the same time may increase the possibility of thrombosis. Avoid directly mixing tranexamic acid with whole blood during a blood transfusion.
Contraindications
Known individual hypersensitivity to the product. Thromboembolic disease, arterial and venous thrombosis, endocavitary hemorrhages, serious kidney failure.
Side Effects
Pregnancy & Lactation
Since the transplacental passage of the drug and its possible effect on the fetus is not clear, tranexamic acid should not be administered during known and suspected pregnancy. Tranexamic acid enters breast milk at a concentration of about one percent of the concentration in maternal blood. It is unlikely to have an antifibrinolytic effect in nursing babies.
Precautions & Warnings
Storage Conditions
Store in a dry place at 15-30°C, away from light, and keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.